Akeso secures NMPA approval for gumokimab to treat ankylosing spondylitis
China's National Medical Products Administration has granted approval for Akeso’s gumokimab to treat active ankylosing spondylitis.

The National Medical Products Administration (NMPA) of China has approved Akeso’s gumokimab, an IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis. The approval follows the successful review of the company's supplemental New Drug Application.
Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the spine. By targeting the IL-17A protein, gumokimab aims to reduce inflammation and manage symptoms for patients struggling with the condition. This development marks a significant shift in Akeso’s therapeutic portfolio as it targets a growing demographic in the autoimmune sector.
Akeso, listed on the Hong Kong Stock Exchange, developed this therapy in-house. Following this regulatory milestone, the company is moving toward full-scale commercialization within China, aiming to compete with existing biologics in the immunology space.